Drug Trial Radar · NCT00145327
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
Last checked: Nov 19, 2026Latest source record: Jun 28, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,456
Actual
Start
May 2005
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 68 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year core study ended. Baseline is the same as Year 3.
Conditions
- Osteoporosis
Interventions
Zoledronic AcidDrug
Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
PlaceboDrug
100 mL physiologic 0.9% normal saline for intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3Time frame: Year 3 (Extension Baseline; Month 36 prior to the first treatment of the extension study) and Year 6 (Month 72; end of extension study)
Locations
31 sites in 2 countries. Site status is shown where the registry gives one.
Southern Arizona VA
Tucson, Arizona
University of Arkansas for Medical Science
Little Rock, Arkansas
Osteoporosis Medical Center
Beverly Hills, California
Osteoporosis Prevention Center
San Diego, California
Diablo Clinical Research, Inc
Walnut Creek, California
Colorado Center for Bone Research
Lakewood, Colorado
CRIA Research
Fort Lauderdale, Florida
Radiant Research
Stuart, Florida
Comprehensive Clinical Trials, LLC
West Palm Beach, Florida
United Osteoporosis Centers (UOC)
Gainesville, Georgia
Northwestern University Center for Clinical Research
Chicago, Illinois
School of Medicine
Indianapolis, Indiana
Medical Specialist Clinical Research Center
Munster, Indiana
Heartland Research Associates, LLC
Wichita, Kansas
Maine Center for Osteoporosis Research and Education
Bangor, Maine
Osteoporosis Clinical Trial Center
Hagerstown, Maryland
Clinical Pharmacology Study Groups
Worcester, Massachusetts
Washington University Center for Clinical Studies
St Louis, Missouri
New Mexico Clinical Research and Osteoporosis Center Inc
Albuquerque, New Mexico
Winthrop U Hospital
Mineola, New York
Odyssey Research Services/CCRC Internal Medical
Fargo, North Dakota
University of Cincinnati Bone Health and Osteoporosis Center
Cincinnati, Ohio
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Radiant Research
Wyomissing, Pennsylvania
Rhode Island Hospital, Endocrinology Clinical Research Unit
Providence, Rhode Island
University of Tennessee Health Science
Memphis, Tennessee
McGuire Veterans Affairs Medical Center
Richmond, Virginia
VA Commonwealth University
Richmond, Virginia
Puget Sound Osteoporosis Center
Seattle, Washington
Novartis
Nuremberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.